Quantbot Technologies LP Reduces Stake in Corcept Therapeutics Incorporated (NASDAQ:CORT)

Quantbot Technologies LP reduced its position in Corcept Therapeutics Incorporated (NASDAQ:CORTFree Report) by 36.0% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 24,182 shares of the biotechnology company’s stock after selling 13,630 shares during the period. Quantbot Technologies LP’s holdings in Corcept Therapeutics were worth $659,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Linden Thomas Advisory Services LLC grew its holdings in shares of Corcept Therapeutics by 0.7% in the third quarter. Linden Thomas Advisory Services LLC now owns 56,116 shares of the biotechnology company’s stock valued at $1,529,000 after purchasing an additional 368 shares in the last quarter. Sei Investments Co. lifted its position in shares of Corcept Therapeutics by 3.0% during the second quarter. Sei Investments Co. now owns 14,565 shares of the biotechnology company’s stock valued at $394,000 after buying an additional 427 shares during the last quarter. Captrust Financial Advisors lifted its position in shares of Corcept Therapeutics by 0.3% during the second quarter. Captrust Financial Advisors now owns 228,167 shares of the biotechnology company’s stock valued at $5,077,000 after buying an additional 621 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its holdings in shares of Corcept Therapeutics by 0.7% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 102,190 shares of the biotechnology company’s stock valued at $2,274,000 after acquiring an additional 746 shares in the last quarter. Finally, Mackenzie Financial Corp increased its holdings in shares of Corcept Therapeutics by 7.0% during the fourth quarter. Mackenzie Financial Corp now owns 11,697 shares of the biotechnology company’s stock valued at $238,000 after acquiring an additional 766 shares in the last quarter. 78.80% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

CORT has been the topic of several research reports. StockNews.com upgraded shares of Corcept Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Wednesday, December 27th. Canaccord Genuity Group increased their target price on Corcept Therapeutics from $37.00 to $38.00 and gave the company a “buy” rating in a research report on Wednesday, December 13th. HC Wainwright decreased their price objective on Corcept Therapeutics from $34.00 to $28.00 and set a “buy” rating on the stock in a report on Tuesday, January 2nd. Finally, Truist Financial upgraded Corcept Therapeutics from a “hold” rating to a “buy” rating and raised their price objective for the company from $29.00 to $38.00 in a report on Monday, November 6th. Three research analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $31.81.

Read Our Latest Research Report on CORT

Corcept Therapeutics Trading Up 2.6 %

Shares of NASDAQ:CORT opened at $22.02 on Wednesday. The business has a 50-day moving average price of $26.38 and a 200 day moving average price of $27.96. The company has a market capitalization of $2.27 billion, a price-to-earnings ratio of 27.19 and a beta of 0.46. Corcept Therapeutics Incorporated has a 12-month low of $17.86 and a 12-month high of $34.28.

Insider Buying and Selling

In related news, insider Gary Charles Robb sold 1,381 shares of the firm’s stock in a transaction dated Tuesday, December 5th. The stock was sold at an average price of $26.27, for a total transaction of $36,278.87. Following the completion of the sale, the insider now directly owns 27,602 shares of the company’s stock, valued at approximately $725,104.54. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, insider William Guyer sold 10,000 shares of the firm’s stock in a transaction dated Friday, December 22nd. The stock was sold at an average price of $32.00, for a total transaction of $320,000.00. Following the completion of the sale, the insider now directly owns 6,643 shares of the company’s stock, valued at approximately $212,576. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Gary Charles Robb sold 1,381 shares of Corcept Therapeutics stock in a transaction dated Tuesday, December 5th. The shares were sold at an average price of $26.27, for a total value of $36,278.87. Following the completion of the transaction, the insider now directly owns 27,602 shares of the company’s stock, valued at $725,104.54. The disclosure for this sale can be found here. In the last ninety days, insiders sold 47,981 shares of company stock valued at $1,278,355. 19.80% of the stock is currently owned by insiders.

About Corcept Therapeutics

(Free Report)

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe metabolic, oncologic, endocrine, and neurological disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery.

See Also

Want to see what other hedge funds are holding CORT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corcept Therapeutics Incorporated (NASDAQ:CORTFree Report).

Institutional Ownership by Quarter for Corcept Therapeutics (NASDAQ:CORT)

Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.